Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ulmus americana pollen extract
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Percutaneous, Subcutaneous, Inhalation, Sublingual
01
Overview
Ulmus americana pollen extract is a non-standardized allergenic extract used for both allergy testing and allergen immunotherapy (hyposensitization therapy). [2] Developed and marketed by companies such as ALK-Abello, Inc. and Greer Laboratories, Inc., it is indicated for patients with immediate hypersensitivity allergies to American elm pollen. The product is a biological solution administered through intradermal, percutaneous, or subcutaneous routes. [7] While often used as a standalone treatment, it can also be a component in multi-allergen mixes like 'Eastern Tree Pollen Mix'. The ALK-Abello product with NDC 0268-1171, first marketed in 1965, has been discontinued.
- Brand names
- Center-Al
- Other names
- American elm pollenUlmus americana pollenAmerican Elm
02
Targets
TCR-Ulmus (T-cell receptor recognizing Ulmus americana-derived peptides)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)
Beyond the preview
Go deeper on ulmus americana pollen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ulmus americana pollen extract.